Association of vitamin D3 with alveolar bone regeneration in dogs

Hsiang-Hsi Hong a, b, Tzung-Hai Yen c, Adrienne Hong d, Ting-An Chou a, b, *

a Department of Periodontics, Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taiwan
b School of Dental Technology, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan
c Department of Nephrology and Division of Clinical Toxicology, Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taiwan
d Department of Integrative Biology, University of California, Berkeley, CA, USA

Received: June 28, 2014; Accepted: September 19, 2014

Abstract

Designed sockets prepared on the mandibles of nine Beagle dogs were divided into three groups: Calcitriol + Alloplast, Alloplast and Empty. Five of the nine dogs received Vit.D3 and calcium supplement (Vit.D/Ca group), while the other four dogs without supplements were assigned to Non-Vit.D/Ca group. After 4 weeks, the extent of vertical ridge resorption (VRR), bone density (density), new bone formation (NBF) and implant stability quotient (ISQ) were measured. Following systemic Vit.D/Ca administration, the Empty subgroup showed significant differences from the Calcitriol + Alloplast subgroup on variants NBF/Density/VRR and the Alloplast subgroup on items NBF/Density/ISQ/VRR. Alternatively, the Calcitriol + Alloplast subgroup revealed higher values of NBF/Density/ISQ (P < 0.001) and a lower VRR value (P = 0.001) than the Alloplast subgroup. Although there were no significant differences in NBF (P = 0.349), density (P = 0.796), ISQ (P = 0.577) and VRR (0.979) comparisons on alloplast treatment between the Vit.D/Ca and Non-Vit.D/Ca groups, local application with Calcitriol + Alloplast demonstrated better NBF/Density/ISQ (P = 0.02 to <0.001) effects than which of Alloplast subgroups. Consequently, the results showed that both systemic and local vitamin D3 treatment might accelerate bone regeneration in dogs. Within the using dose, systemic vitamin D3 treatment displayed a superior stimulating effect than local vitamin D3 application did.

Keywords: alloplast ● bone regeneration ● calcitriol ● cholecalciferol ● vitamin D3 ● ridge preservation

Introduction

Many human and animal trials have studied the effects of ridge preservation by placing various bone grafts and substitutes into extraction sockets or created defects. However, the bone quantity and quality at the regenerated sites have been inconsistent to date.

Local biphasic calcium phosphate ceramic (BCP) application into the fresh extraction sockets of dogs promoted the morphologic preservation of the alveolar ridge significantly in 3 months [1]. Synthetic bone grafts were referred to serve as scaffolds for bone formation, maintain space for bone growth, and promote wound healing by stabilizing blood clots [2]. However, the osseoinduction potential by using synthetic bone grafts alone is limited [3]. Several studies have documented that growth factors can enhance bone regeneration [3–5] and the regenerative capability of growth factors depends greatly on the method of being applied [6]. More than enhanced the bone regeneration significantly, a combination of growth factors and synthetic bone ceramic (or polymeric) grafting materials allowed the sustained release and reduced the dosage of growth factors.

An early report declared irrelevancy between vitamin D metabolites and bone formation in rats [7]. However, many animal models supported the positive correlation between bone healing and systemic vitamin D3 supplement, in which the vitamin D3 metabolites promoted the repair of bone fractured and increased the calcius strength in chickens, rats and rabbits [8–11]. Human studies demonstrated that vitamin D3 and calcium supplementation not only reduced hip bone resorption and fracture rates [12–15] but they also increased vertebral bone density and total body calcium in post-menopausal women with vitamin D3 supplementation of 10 μg/day and an adjusted calcium intake of 1000 mg/day [16].

*Correspondence to: Ting-An CHOU, Department of Periodontics, Chang Gung Memorial Hospital, 5, Fu-Shin Street, Kweishan 333, Taoyuan, Taiwan.
Tel.: +886 3 3281200 ext 8326 Fax: +886 3 3281200 ext 8320 E-mail: f1214@adm.cgmh.org.tw
doi: 10.1111/jcmm.12460
However, the studies that explore the distinct effect of systemic vitamin D3 supplement and local vitamin D3 application on bone healing after traumatic fracture, pathologic defects, or surgically created defects in large animal are rare.

A dog’s study reported that the combination of calcium supplementation and vitamin D3 might have systemic effects in accelerating alveolar bone regeneration [17]; however, the local effect of vitamin D3 relevance remains undetermined. Recent evidence suggested that calcitriol and its associated metabolites might stimulate bone mineralization directly: In vitro studies have revealed that the vitamin D receptor is present in osteoblasts and that calcitriol directly affects the ability of osteoblasts to regulate the expression of several genes. Subsequently, the proliferation of osteoblasts and the production of type I collagen, alkaline phosphatase and osteocalcin intensify; these verifications provide further support for the regulatory function of the vitamin D in bone formation and mineralization [16, 18, 19]. In addition, incorporating a biodegradable polyurethane bone graft substitutes with vitamin D3 could enhance bone regeneration of bicortical defects in the iliac crest of oestrogen-deficient sheep [20]. On the basis of these studies, it has been suggested that calcitriol might exert a local effect on alveolar bone regeneration as well. The first aim of the current experiment was to explore the regenerative possibility of active vitamin D3 (calcitriol), which was applied locally to surgically created defects during the experimental period. The other aim of this trial was to compare the possible regeneration effects of systemically vitamin D3 administration (containing calcium and cholecalciferol supplement) to that of localized vitamin D3 (calcitriol) application on the created defects in alveolar bone of dogs during the early healing stage.

Materials and methods

Animals

The animal ethical committee of Chang Gung Memorial Hospital (CGMH) granted this research protocol. Nine Beagle dogs that were approximately 1 year old and weighed 10–15 kg each were employed in the study.

Agents and biomaterials

Bonagraft (San Chung, New Taipei City, BioTech One, Taiwan) a synthetic BCP alloplast (HA/β-TCP) containing 60% hydroxyapatite (HA)/40% beta tri-calcium phosphate (β-TCP) of 250–500 μm in size, was adopted to preserve the prepared ridges in this study. Calcijex® (Hospira Inc. for Abbott Laboratories, Rocky Mount, NC, USA) is an active form of vitamin D3 (calcitriol; 1α, 25(OH)2D3), which contains 1 ml of 80 IU calcitriol. One millilitre of Calcijex® mixed with 0.5 g of alloplast was inserted into a defect. In addition, Calcijex® was further injected submucously around the Calcitriol + Alloplast sites every 7 days on the right mandibles of Vit.D/Ca and Non-Vit.D/Ca groups. In the Vit.D/Ca group, every dog was fed additionally six oral Tablets of Bio-cal® per day that each Tablet was composed of 802 mg tri-calcium phosphate (TCP, equivalent to 300 mg calcium) and 1.56 μg cholecalciferol. Both Bio-cal® and Calcijex® were provided by the CGMH pharmacy.

Experimental design

The dogs were randomly divided into two groups. Five dogs receiving Bio-cal® supplementation were assigned to the treatment group (Vit.D/Ca group); the other five dogs without Bio-cal® supplement were assigned to the control group (Non-Vit.D/Ca group), however, one of the five dogs was excluded because of inadequate bodyweight. The sockets on each mandible were divided into three treatment modalities: four sockets on the right side were grafted with 1 ml of Calcijex® and 0.5 g of HA/β-TCP (Calcitriol + Alloplast subgroup); two of the four sockets on the left side were randomly grafted with HA/β-TCP (Alloplast subgroup) and the other two defects were left empty (Empty subgroup).

Surgical procedure

All surgical procedures were performed in the animal laboratory of CGMH. To reduce salivation, a subcutaneous premedication of atropine (0.05 mg/kg s.c.) was applied to the dogs prior to surgery. Fifteen minutes later, the generalized anaesthesia were induced intramuscularly with Zoletil 50® (10–15 mg/kg) and maintained on 0.5–2% isoflurane/oxygen via a cuffed endotracheal tube. Veterinarians in the animal laboratory also performed the pre-operative analgesia procedure. Under aseptic routines, mandibular nerve block (2% lidocaine hydrochloride at a total dose of 2 mg/kg) was administered and the premolars on both sides of the mandible were extracted during the initial stage of the study. Three months later, four standardized cylindrical sockets with 4.0 mm in diameter and 6 mm in depth were prepared on both sides of the mandible after flap operation. The socket defects were divided into three local treatment modalities, as described above (Fig. 1A).

Data collection

After a 4-week healing period, the amount of vertical ridge resorption (VRR) was evaluated according to a surgical stent (Fig. 1B). The bone cores 3.0 mm in diameter and 6 mm deep were drawn with a 4.0 mm outer diameter trephine bur from the sites determined by the surgical stent, and placed in a fixative for histomorphometric analysis (Fig. 1C). Subsequently, an implant (ITI Straumann®) with 4.8 mm in diameter and 6.0 mm in length was inserted and the implant stability quotient (ISQ) was measured with Osstell® (Ostell AB, Gamlestadsvägen 3B, SE 415 02 Göteborg, Sweden) immediately after implant placement by performing resonance frequency analysis (Fig. 1D). To reduce experimental error, the same investigators repeated all measurements and averaged the two closest values.

Post-surgical procedure

After surgery, the dogs were placed in cages warmed on a circulating water heating pad and kept under observation for signs of distress until they were able to move normally. Post-operative analgesia with an oral
non-steroidal anti-inflammatory was administered every 8–12 hrs for 2 days. A soft-pellet diet was fed to these dogs throughout the survey. The dogs assigned to the Vit.D/Ca group were given six Tablets of Bio-cal/C226 every day for 4 weeks [21]. At the end of the experiment, the dogs were killed with an overdose of Pentothal Natrium perfused through the carotid arteries, with a fixative containing a mixture of 5% glutaraldehyde and 4% formaldehyde.

**Cone beam computed tomography analysis**

Cone beam computed tomography (CBCT) scans with 0.25-mm-thick slices were obtained for each bone block point on an iCAT CBCT machine (Imaging Sciences International, Hatfield, PA, USA). An installed computed tomography program determined the bone density, which was described by a Hounsfield unit (HU) value.

**Histotechnical preparation and histometric analysis**

Each block, 3.0 mm in diameter and 6 mm tall, was decalcified in ethylenediaminetetraacetic acid, dehydrated in increasing concentrations of ethanol, embedded in paraffin, and cut horizontally by the pathology department. The sections were stained in haematoxylin and eosin. The middle sections of the bony cores, representing the central portion (in a subcrestal cross-section 3 mm in area), from each group were selected and subjected to histological evaluation. Histological images were taken using a digital camera (Nikon Diaphot 300, Southern Micro Instruments, Atlanta, GA, USA) attached to an inverted microscope (Olympus BX51 Microscope, Hatagaya, Shibuya-ku, Tokyo, Japan) equipped with a ×10 objective lens. The area of new bone formation (NBF) was measured in pixels using digital imaging software (Image J, National Institutes of Health, Bethesda, MD, USA) and expressed as a percentage of NBF (Fig. 1).

**Statistical analysis**

Group means and standard deviations were calculated for each measured parameter. Information regarding the percentage of NBF, bone density (Hu) at preparation sites, ISQ and VRR achieved from surgical sites was evaluated using ANOVA and LSD tests. The ANOVA and LSD tests approach were employed to determine whether a systemic supplement of Vit.D/Ca and the three various local treatments affected bone defect regeneration. A P < 0.05 was considered significant. As ANOVA and LSD tests account for possible correlations of bone regeneration at different locations within a patient, they can also be used to measure the significance of possible covariates. The application of ANOVA and LSD tests in this study were intended to model dependent variables (NBF, density, ISQ and VRR) as a function of local treatment or Vit.D/Ca supplement. Before and after survey, the examined serum items [intact parathyroid hormone (PTH), calcium, phosphorus and 25-OH-D3] were monitored by Mann–Whitney test (P < 0.05).

**Results**

In generalized aspects (Tables 1 and 2), the dogs receiving a Vit.D/Ca supplement exhibited more NBF (33.68 ± 14.87% versus 22.96 ± 10.30%, P = 0.001) and higher bone density (1156.92 ± 438.19 Hu versus 890.06 ± 300.76 Hu, P = 0.006) than those without Vit.D/Ca supplement. On the other hand, from the viewpoint of local expression, the Empty subgroup achieved higher values of NBF (42.35 ± 12.52%), density (1373.29 ± 367.05 Hu), ISQ (75.06 ± 5.24) and VRR (2.45 ± 0.34 mm) than the other two subgroups (P < 0.001). Furthermore, the Calcitriol + Alloplast (HA/β-TCP) subgroup also revealed higher values of NBF (42.35 ± 12.52%), density (1373.29 ± 367.05 Hu), ISQ (75.06 ± 5.24) and VRR (2.45 ± 0.34 mm) than the other two subgroups (P < 0.001).
As shown in Figure 2 and Table 3, non-significant NBF difference was noted in the Alloplast subgroups between Vit.D/Ca and Non-Vit.D/Ca groups ($P = 0.349$), neither were the Empty subgroup of Non-Vit.D/Ca group and the Calcitriol/Alloplast subgroup of Vit.D/Ca group ($P = 0.706$). Comparing to the Alloplast subgroup of Vit.D/Ca group, the Calcitriol/Alloplast subgroup of Non-Vit.D/Ca group demonstrated a statistic effect of non-difference ($P = 0.131$). Except that, all subgroups demonstrated significant NBF differences to each other, such as local treatment with Calcitriol + Alloplast caused significantly greater NBF value than that occurred in the Alloplast variants no matter with Vit.D/Ca ($P < 0.001$) or without Vit.D/Ca ($P = 0.020$) supplement.

The relationship of the density among various subgroups showed that non-significant difference was found in the Alloplast subgroups between Vit.D/Ca and Non-Vit.D/Ca groups ($P = 0.796$), neither was the Empty subgroup of Non-Vit.D/Ca group and the Calcitriol + Alloplast subgroup of Vit.D/Ca group ($P = 0.327$). Furthermore, in Non-Vit.D/Ca group, the Empty subgroup and the Calcitriol/Alloplast subgroup did not display a statistic difference ($P = 0.073$). However, both Calcitriol + Alloplast and Empty subgroups revealed higher Hu values than which of Alloplast subgroups in both Vit.D/Ca group and Non-Vit.D/Ca group (from $P < 0.001$ to $P = 0.002$). The Empty subgroups presented a significant density difference between Vit.D/Ca group and Non-Vit.D/Ca group ($P = 0.009$). In Vit.D/Ca group, the Empty subgroup also displayed a statistically higher density than that of the Calcitriol/Alloplast subgroup ($P = 0.021$, Table 4).

Comparing to the Empty subgroups, adding Alloplast diminished the ISO in Vit.D/Ca group and Non-Vit.D/Ca group significantly ($P < 0.001$ and $P = 0.034$ respectively, Table 5). In addition, systemic cholecalciferol/Ca supplement did not up-regulate more ISO values for all three subgroups than Non-Vit.D/Ca group ($P = 0.720$ in Calcitriol + Alloplast, $P = 0.577$ in Alloplast and $P = 0.471$ in Empty...
subgroups). However, local calcitriol applications compensated the compromised ISQ that originated from alloplast appendage (P < 0.001 in Vit.D/Ca group and P = 0.005 in Non-Vit.D/Ca group respectively) and derived to the ISQs comparable to Empty groups (P = 0.326 in Vit.D/Ca group and P = 0.826 in Non-Vit.D/Ca group).

Ridge preservation by alloplast, no matter with or without calcitriol application, resulted in less VRR than Empty subgroups (P < 0.001) in both Vit.D/Ca and in Non-Vit.D/Ca groups. Systemic Vit.D/Ca supplement could lessen VRR in Calcitriol + Alloplast (P < 0.001) and Empty (P < 0.001) subgroups than which of Non-Vit.D/Ca group. However, local calcitriol application only affected the VRR effect of alloplast in Vit.D/Ca group (P < 0.001), but not in Non-Vit.D/Ca group (P = 0.695, Table 6).

Comparing to the baseline examination, the prescribed Vit.D/Ca supplement decreased serum levels of intact PTH (P = 0.018), 25-OH-D₃ (P = 0.003) and phosphorus (P = 0.042) significantly. On the other hand, only serum 25-OH-D₃ levels were influenced significantly by local calcitriol application (P = 0.005).

In contrast to systemic Vit.D/Ca supplement, local calcitriol application revealed a significant increase in serum intact PTH levels (P = 0.019) and a significant decrease in serum 25-OH-D₃ levels (P = 0.027, Table 7).

### Discussion

Up to now, limited evidence are available to support the idea of taking vitamin D₃ and calcium supplementation (Vit.D₃/Ca) may stimulate early bone healing and accelerate bone quality and quantity in the alveolar sockets of dogs. The results of this study correspond to some previous reports and demonstrate that taking Vit.D/Ca supplementation during the early stage of socket healing promotes more

---

**Table 3** Comparison of the new bone formation (NBF) among various subgroups

| NBF (%) | Vit.D/Ca | Non-Vit.D/Ca |
|---------|----------|--------------|
|         | Calcitriol + Alloplast | Alloplast | Empty | Calcitriol + Alloplast | Alloplast | Empty |
|         | 35.24 ± 11.21 | 17.49 ± 5.04 | 48.19 ± 12.36 | 23.28 ± 9.28 | 13.13 ± 4.50 | 33.58 ± 6.40 |

Vit.D/Ca

|        | Calcitriol + Alloplast | Alloplast | Empty | Calcitriol + Alloplast | Alloplast | Empty |
|--------|------------------------|-----------|-------|------------------------|-----------|-------|
|        | <0.001***              | 0.001**   |       | <0.001***              | 0.706     |       |
|        | <0.001***              | 0.131     | 0.349 | 0.001**                |           |       |
|        | <0.001***              |           | <0.001*** | 0.004**                |           |       |
| Non-Vit.D/Ca
|        | Calcitriol + Alloplast |           |       |                        |           |       |
|        | 0.020*                 |           |       |                        |           |       |
|        | Alloplast               |           |       |                        |           |       |
|        | Empty                   |           |       | <0.001***              |           |       |

Significant differences among most various groups were examined using ANOVA and LSD tests.

NBF, new bone formation.

***P < 0.001, **P < 0.01, *P < 0.05.

---

Fig. 2 The effects of vitamin D₃ on alveolar bone regeneration in dogs were examined under microscopic observation (haematoxylin and eosin stain, original magnification ×10). (A) Empty defect in an individual receiving Vit.D/Ca supplement. (B) Empty defect in an individual without Vit.D/Ca supplement. (C) Calcitriol + alloplast defect in an individual receiving Vit.D/Ca supplement. (D) Calcitriol + alloplast defect in an individual without Vit.D/Ca supplement. (E) Alloplast defect in an individual receiving Vit.D/Ca supplement. (F) Alloplast defect in an individual without Vit.D/Ca supplement.
NBF, higher bone density and less VRR when compared to a non-supplement group (Table 2). However, taking Vit.D/Ca supplement does not contribute to enhancing the implant stability in the investigational areas of this study. The fact may be explained by that the newly formed bone is not mature enough to respond the ISQ examination. A longer healing period might be required to promote a better implant stability and achieve a higher ISQ value.

Although the outcome of compromised ISQ value, less NBF and lower bone density that associated with the grafting HA/bTCP alloplast are found on both Vit.D/Ca and Non-Vit.D/Ca groups; local calcitriol application demonstrates an improving effect on NBF ($P = 0.020$, Table 3), bone density ($P = 0.002$, Table 4) and ISQ value ($P = 0.005$, Table 5) than which of the HA/bTCP grafted sockets. The benefit of local calcitriol application on bone regeneration in this observation may be rationalized partially by previous in vitro studies [16, 18, 19].

When exploring the effect of local vitamin D3 delivery on the supporting bone around the teeth after orthodontic treatment, the findings of studies concluded that the use of calcitriol might eventually enhance bone remodelling or regeneration of the supporting bone [22–25]. Meanwhile, a chicken study noted that certain vitamin D derivatives might possess various healing properties and concluded that 24,25-dihydroxyvitamin D3 might increase bone healing and prevent the complication rate of non-union. Although the role of bone-wax was not explored, calcitriol decreased callus strength when 50 mg of bone-wax containing 5 μg of calcitriol or 24,25-dihydroxyvitamin D3 was applied on the fractured site [26]. Therefore, the local effect of vitamin D3 on bone regeneration remains controversial. Disparate methods and materials may account for the variation; the present study does not find the corresponding clinical or microscopic side effects after local calcitriol application to concur the previous evidence [27]. According to our knowledge, although local calcitriol effect without carrier on empty sockets was not tested, this study is the first report to suggest that local application of active vita-

| Table 4 Relationship of the Density among various subgroups |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Density | Vit.D/Ca | Non-Vit.D/Ca | Empty | Vit.D/Ca | Non-Vit.D/Ca | Empty |
| (Hu) | Calcitriol + Alloplast | Alloplast | Empty | Calcitriol + Alloplast | Alloplast | Empty |
| 1273.68 ± 236.56 | 598.28 ± 233.04 | 1518.18 ± 383.44 | 932.34 ± 229.20 | 565.53 ± 229.91 | 1155.96 ± 218.00 |

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ by ANOVA and LSD tests.
and variable healing time intervals. In the present investigation, the alloplast applied delayed NBF, reduced bone density, and decreased ISQ reading during the early stage of socket healing. These results are comparable to previous animal studies [38–40], which resulted in reduced NBF and delayed initial healing in fresh extraction sockets filled with deproteinized bovine bone in combination with collagen. The assumption is that the employed bone substitute provided a scaffold for space maintenance and osteoconduction at the expense of compromising blood supply and interfering with the normal healing process in the tested areas. Hence, bone regeneration with a bone substitute may help to retain the ridge contour better than spontaneous healing, but may also require a longer healing period to generate a better quality and quantity of bone, which has an impact on subsequent implant surgery as dental implants rely on the availability of vital bone to achieve osseointegration [41]. Similarly to the previous studies [28, 30, 31, 42], current investigation supports that grafted alloplast minimize vertical resorption of the alveolar ridge but prevent the normal healing process of the extraction socket during the early-phase of bone healing.

The results demonstrate that systemic Vit.D/Ca supplement seems does not assist to increase more NBF (\( P = 0.349 \)) and density (\( P = 0.796 \)) in Alloplast subgroup than without taking supplement. On the other hand, employing Vit.D/Ca supplement and/or local calcitriol application could up-regulate the diminished NBF (\( P < 0.001 \) in Vit.D/Ca group and \( P = 0.020 \) in Non-Vit.D/Ca group respectively, Table 3) and density (\( P < 0.001 \) in Vit.D/Ca group and \( P = 0.002 \) in Non-Vit.D/Ca group respectively, Table 4) caused by HA/pTCP alloplast graft. Systemic Vit.D/Ca supplement also enhance NBF and

| ISQ (0–100) | With Vit.D/Ca | Alloplast | Empty | Non-Vit.D/Ca | Alloplast | Empty |
|------------|--------------|----------|-------|-------------|----------|-------|
| Vit.D/Ca   |              |          |       |             |          |       |
| Calcitriol + Alloplast | <0.001*** | 0.326    | 0.720 | 0.008**     | 0.974    |       |
| Alloplast  | <0.001***    | <0.001***| 0.577 | 0.006**     |          |       |
| Empty      |              | 0.509    | 0.002**| 0.471       |          |       |
| Non-Vit.D/Ca|            |          |       |             |          |       |
| Calcitriol + Alloplast |          | 0.005** | 0.826 |            |          |       |
| Alloplast  |              |          | 0.034* |            |          |       |
| Empty      |              |          |       |            |          |       |

* \( P < 0.05 \), ** \( P < 0.01 \), *** \( P < 0.001 \) by ANOVA and LSD tests.

| VRR (mm) | With Vit.D/Ca | Alloplast | Empty | Non-Vit.D/Ca | Alloplast | Empty |
|----------|--------------|----------|-------|-------------|----------|-------|
| Vit.D/Ca |              |          |       |             |          |       |
| Calcitriol + Alloplast | 0.001**    | <0.001***| 0.001**| 0.004**     | <0.001***|       |
| Alloplast | <0.001***    | 0.636    | 0.979 | <0.001***   |          |       |
| Empty    |              | <0.001***| <0.001***| <0.001***  |          |       |
| Non-Vit.D/Ca|            |          |       |             |          |       |
| Calcitriol + Alloplast |          | 0.695    | <0.001***|            |          |       |
| Alloplast |              |          | <0.001***|            |          |       |
| Empty    |              |          |       |            |          |       |

** \( P < 0.01 \), *** \( P < 0.001 \) by ANOVA and LSD tests.
density effects in Calcitriol + Alloplast (P < 0.001 in Tables 3 and 4) and Empty (P = 0.004 in Table 3 and 0.009 in Table 4) subgroups (Tables 3 and 4).

Consist with other studies, the results of this study support the theory that alloplast may impede NBF, healing bone density and implant stability. On the other hand, alloplast assist to reduce the amount of VRR. Our results also confirm that taking systemic Vit.D/Ca supplement may downstage significantly VRR for Empty (P < 0.001) subgroup (Table 6). However, systemic Vit.D/Ca supplement seems does not lessen VRR in Alloplast subgroup than without taking supplement (P = 0.979). At given dose, local calcitriol application for Alloplast subgroup does not offer a better effect of decreasing VRR than without calcitriol application (P = 0.695) in Non-Vit.D/Ca group. Nevertheless, once cholecalciferol/Ca supplement was provided, Calcitriol + Alloplast subgroup exhibit a significant less VRR than Alloplast subgroup (P = 0.001) in Vit.D/Ca group.

Generally, the inspected blood variants demonstrate a normally adjustment on both Vit.D/Ca and Non-Vit.D/Ca groups before and after this survey (Table 7). However, only serum calcium changes non-significantly following systemic and/or localized vitamin application. The feedback effect of vitamin D3 may explain the findings that serum intact PTH, phosphorus and 25-OH-D3 decrease significantly subsequent to systemic Vit.D/Ca supplement and local calcitriol taking. However, the inclination of increasing PTH level without calcium supplement on local calcitriol group needed to be decided by further studies. The different characteristics of calcitriol and cholecalciferol/Calcitriol + Alloplast (P < 0.001) causes a higher intact PTH value than Vit.D/Ca group. We are unsure of the amount of lethal dose of systemic Vit.D/Ca supplement used (1800 mg calcium/day) for a 15 kg dog; the normal range of calcium, vitamin D3 and phosphorus blood data imply that the dose of vitamin D3 and calcium supplement administered to the dogs was controlled by their metabolism. On the other hand, the intact PTH reading declined significantly to out of reference range indicate that the offered vitamin D3 and calcium supplement was an over dose for the tested dogs. Further researches are required to illuminate these findings. Additionally, in comparison to a previous animal study, our results also demonstrate that a local injection of vitamin D3 does not cause serum levels of calcium, phosphorus, PTH or 25-OH-D3 to shift out of the normal range [27]. Though, the applied local calcitriol dose may initiate a significant drop of serum 25-OH-D3.

Within the limitations of this animal study, which included observing the early healing characteristics of artificial defects, our results support that local calcitriol application may accelerate NBF, increase bone density and improve implant stability in surgically produced alveolar sockets treated with 40% HA/60% β-TCP alloplast for both non-Vit.D/Ca and Vit.D/Ca groups. Relating the Calcitriol/Alloplast subgroups of Non-Vit.D/Ca and Vit.D/Ca groups, the comparison show that local calcitriol application may produce less NBF, lower bone density and less ridge preservation effects than which systemic vitamin D3 can at the given dose. Less amount of accumulated

### Table 7 Differentiation of the blood tests in dogs taking systemic Vit.D/Ca supplement to those receiving local Vit.D3 (Non-Vit.D/Ca) application

| Dog number | Before study (n = 9) | Sys Vit.D/Ca + Loc Vit.D3 (n = 5) | Loc Vit.D3 (n = 4) | P-value |
|------------|---------------------|----------------------------------|-------------------|---------|
| Tested items (normal range) | | | | |
| Intact PTH (1–4 pg/ml) | 11.01 ± 0.105 | 11.02 ± 0.538 | 0.937 |
| | 11.01 ± 0.105 | 11.28 ± 0.421 | 0.222 |
| | 11.28 ± 0.421 | 11.02 ± 0.538 | 0.539 |
| Serum Phos (2.1–6.3 mg/dl) | 1.92 ± 1.109 | 2.53 ± 0.350 | 0.118 |
| | 0.44 ± 0.984 | 2.53 ± 0.350 | 0.018* |
| | 0.44 ± 0.984 | 2.53 ± 0.350 | 0.019* |
| 25-OH-D3 (25–200 nmol/l) | 5.43 ± 0.482 | 4.75 ± 0.695 | 0.139 |
| | 5.43 ± 0.482 | 4.7 ± 0.644 | 0.042* |
| | 4.7 ± 0.644 | 4.75 ± 0.695 | 0.902 |
| | 31.67 ± 0.84 | 27.45 ± 0.412 | 0.005* |
| | 28.68 ± 0.672 | 27.45 ± 0.412 | 0.003* |
| | 28.68 ± 0.672 | 27.45 ± 0.412 | 0.027* |

Sys Vit.D/Ca + Loc Vit.D3, Systemic Vit.D/Ca + Local Vit.D3 treatment; Loc Vit.D3, Local Vit.D3 application; Intact PTH, Intact parathyroid hormone; Serum Ca, Serum Calcium level; 25-OH-D3, Serum 25-OH-vitamin D3; Serum Phos, Serum Phosphorus level. *P < 0.05 by Mann-Whitney test.
Vitamin D₃ dose on Non-Vit.D/Ca group may partially explain the finding. The grafted bone substitute preserve the alveolar ridges significantly, however, the undesirable results of less NBF, inferior bone density and compromised implant stability may associate. Both systemic supplements of cholecalciferol/calcium and local calcitriol application seem significantly minimize the influences.

Further studies are required to determine not only a proper amount of systemic vitamin D₃ and calcium supplement but also the effective dose and method for local vitamin D₃ delivery. Solid evidence are still necessitated to support the possible effects of vitamin D₃ on bone regeneration at earlier and later stages in animals and humans.

Acknowledgements

Dr Hsiang-Hsi Hong was funded by research grants from National Science Council of Taiwan (102-2314-B-182A-041) and Chang Gung Memorial Hospital (CMRP 370291, 392071, 3A1141, 3A1142), respectively. An affidavit gave approval for the animal use protocol (CGMH 2007101501). Dr Tsung-Hai Yen is also affiliated with Kidney Research Center and Center for Tissue Engineering, Chang Gung Memorial Hospital at Linkou, Taiwan.

Conflicts of interest

The authors confirm that there are no conflicts of interest.

References

1. Boix D, Weiss P, Gauthier O, et al. Injectable bone substitute to preserve alveolar ridge resorption after tooth extraction: a study in dog. J Mater Sci Mater Med. 2006; 17: 1145–52.
2. Shiratori K, Matsuoka K, Koike Y, et al. Bone formation in beta-tricalcium phosphate-filled bone defects of the rat femur: morphological analysis and expression of bone related protein mRNAs. Biomed Res. 2005; 26: 51–9.
3. Precheur HV. Bone graft materials. Dent Clin North Am. 2007; 51: 729–46, viii.
4. Cho MI, Lin WL, Genco RJ. Platelet-derived growth factor-modulated guided tissue regenerative therapy. J Periodontol. 1995; 66: 522–30.
5. Jung RE, Glauer S, Scharer P, et al. Effect of rhBMP-2 on guided bone regeneration in humans. Clin Oral Implants Res. 2003; 14: 556–68.
6. Signore A, Picarelli A, Chianelli M, et al. Interleukin-2 scintigraphy: a new approach to assess disease activity in autoimmunity. J Pediatr Endocrinol Metab. 1996; 9(Suppl. 1): 139–44.
7. Thorngren KG, Johnell O, Hansson LL. Influence of 25-OHDS and 1,25-(OH)₂D₃ on bone growth and remodeling in the rat. Acta Anat (Basel). 1983; 117: 31–41.
8. Brumbaugh PF, Speer DP, Pitt MJ. 1 alpha, 25-Dihydroxyvitamin D₃ as a metabolite of vitamin D that promotes bone repair. Am J Pathol. 1982; 106: 171–9.
9. Dekel S, Salama R, Edelstein S. The effect of vitamin D and its metabolites on fracture repair in chicks. Clin Sci (Lond). 1983; 65: 429–36.
10. Delgado-Martinez AD, Martinez ME, Carrascal MT, et al. Effect of 25-OH-vitamin D on fracture healing in elderly rats. J Orthop Res. 1998; 16: 650–3.
11. Omeroglu H, Ates Y, Akkus O, et al. Biomechanical analysis of the effects of single high-dose vitamin D₃ on fracture healing in a healthy rabbit model. Arch Orthop Trauma Surg. 1997; 116: 271–4.
12. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D₃ and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992; 327: 1637–42.
13. Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D₃ supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int. 2002; 13: 257–64.
14. Chen JT, Shiraki M, Hasumi K, et al. 1-alpha-Hydroxyvitamin D₃ treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone. 1997; 20: 557–62.
15. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997; 337: 670–6.
16. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med. 1990; 113: 649–55.
17. Hong HH, Chou TA, Yang JC, et al. The potential effects of cholecalciferol on bone regeneration in dogs. Clin Oral Implants Res. 2012; 23: 1187–92.
18. Miyahara T, Simoura T, Osahune N, et al. A highly potent 26,27-Hexafluoro-1a,25-dihydroxyvitamin D₃ on calcification in SV40 transformed human fetal osteoblastic cells. Calcif Tissue Int. 2002; 70: 488–95.
19. van Leeuwen JP, van Driel M, van den Bemd GJ, et al. Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit Rev Eukaryot Gene Expr. 2001; 11: 199–226.
20. Gogolewski S, Gorna K, Turner AS. Regeneration of bicortical defects in the iliac crest of estrogen-deficient sheep, using new biodegradable polyurethane bone graft substitutes. J Biomed Mater Res A. 2006; 77: 802–10.
21. Doetsch AM, Faber J, Lynnerup N, et al. The effect of calcium and vitamin D₃ supplementation on the healing of the proximal humerus fracture: a randomized placebo-controlled study. Calcif Tissue Int. 2004; 75: 183–8.
22. Boyce RW, Weisbrode SE. Histogenesis of hyperosteoidosis in 1,25(OH)₂D₃-treated rats fed high levels of dietary calcium. Bone. 1985; 6: 105–12.
23. Erben RG, Scott AM, Miao D, et al. Short-term treatment of rats with high dose 1,25-dihydroxyvitamin D₃ stimulates bone formation and increases the number of osteoblast precursor cells in bone marrow. Endocrinology. 1997; 138: 4629–35.
24. Kawakami M, Takano-Yamamoto T. Local injection of 1,25-dihydroxyvitamin D₃ enhanced bone formation for tooth stabilization after experimental tooth movement in rats. J Bone Miner Metab. 2004; 22: 541–6.
25. Terai K, Takano-Yamamoto T, Ohba Y, et al. Role of osteopontin in bone remodeling caused by mechanical stress. J Bone Miner Res. 1999; 14: 839–49.
26. Lidor C, Dekel S, Meyer MS, et al. Biochemical and biomechanical properties of avian calcius after local administration of dihydroxylated vitamin D metabolites. J Bone Joint Surg Br. 1990; 72: 137–40.
27. Takano-Yamamoto T, Kawakami M, Kobayashi Y, et al. The effect of local application...
of 1,25-dihydroxycholecalciferol on osteoclast numbers in orthodontically treated rats. J Dent Res. 1992; 71: 53–9.

28. Becker W, Becker BE, Caffesse R. A comparison of demineralized freeze-dried bone and autologous bone to induce bone formation in human extraction sockets. J Periodontol. 1994; 65: 1128–33.

29. Wang HL, Kiyonobu K, Neiva RF. Socket augmentation: rationale and technique. Implant Dent. 2004; 13: 286–96.

30. Becker W, Urist M, Becker BE, et al. Clinical and histologic observations of sites implanted with intraoral autologous bone grafts or allografts. 19 human case reports. J Periodontol. 1996; 67: 1025–33.

31. Froum S, Cho SC, Rosenberg E, et al. Histological comparison of healing extraction sockets implanted with bioactive glass or demineralized freeze-dried bone allograft: a pilot study. J Periodontol. 2002; 73: 94–102.

32. Feuille F, Knapp CI, Brunsvold MA, et al. Clinical and histologic evaluation of bone-replacement grafts in the treatment of localized alveolar ridge defects. Part 1: mineralized freeze-dried bone allograft. Int J Periodontics Restorative Dent. 2003; 23: 29–35.

33. Artzi Z, Tal H, Dayan D. Porous bovine bone mineral in healing of human extraction sockets. Part 1: histomorphometric evaluations at 9 months. J Periodontol. 2000; 71: 1015–23.

34. Serino G, Biancu S, Iezzi G, et al. Ridge preservation following tooth extraction using a polylactide and polyglycolide sponge as space filler: a clinical and histological study in humans. Clin Oral Implants Res. 2003; 14: 651–8.

35. Cardaropoli G, Araujo M, Hayacibara R, et al. Healing of extraction sockets and surgically produced - augmented and non-augmented - defects in the alveolar ridge. An experimental study in the dog. J Clin Periodontol. 2005; 32: 435–40.

36. Shi B, Zhou Y, Wang YN, et al. Alveolar ridge preservation prior to implant placement with surgical-grade calcium sulfate and platelet-rich plasma: a pilot study in a canine model. Int J Oral Maxillofac Implants. 2007; 22: 656–65.

37. Barone A, Aldini NN, Fini M, et al. Xenograft versus extraction alone for ridge preservation after tooth removal: a clinical and histomorphometric study. J Periodontol. 2008; 79: 1370–7.

38. Araujo M, Linder E, Wennstrom J, et al. The influence of Bio-Oss Collagen on healing of an extraction socket: an experimental study in the dog. Int J Periodontics Restorative Dent. 2008; 28: 123–35.

39. Araujo M, Linder E, Lindhe J. Effect of a xenograft on early bone formation in extraction sockets: an experimental study in dogs. Clin Oral Implants Res. 2009; 20: 1–6.

40. Mardas N, Chadha V, Donos N. Alveolar ridge preservation with guided bone regeneration and a synthetic bone substitute or a bovine-derived xenograft: a randomized, controlled clinical trial. Clin Oral Implants Res. 2010; 21: 688–98.

41. Thoma DS, Dard MM, Halg GA, et al. Evaluation of a biodegradable synthetic hydrogel used as a guided bone regeneration membrane: an experimental study in dogs. Clin Oral Implants Res. 2012; 23: 160–8.

42. Heberer S, Al-Chawaf B, Hildebrand D, et al. Histomorphometric analysis of extraction sockets augmented with Bio-Oss Collagen after a 6-week healing period: a prospective study. Clin Oral Implants Res. 2008; 19: 1219–25.